Efficacy and Safety of Azacitidine in Patients With RUNX1::RUNX1T1 Measurable Residual Disease-Positive Acute Myeloid Leukemia After Consolidation Therapy Who Did Not Undergo Allogeneic Hematopoietic Stem-Cell Transplantation

Clinical Lymphoma, Myeloma & Leukemia · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles